For its third fiscal quarter (ending September 30), IDEXX Laboratories Inc (NASDAQ: IDXX) has reported a 11% increase in E.P.S. from $2.55 a year ago to $2.83 in the current quarter. For the latest four quarters through September 30, E.P.S. were $10.46 versus $9.91 for the same period a year ago — an increase of 6%.
Recent Price Action
IDEXX Laboratories Inc (NASDAQ: IDXX) stock suffered a large decline of -9.8% on 10/31/24. The stock closed at $406.92. Moreover, trading volume in this decline was exceptionally high at 413% of normal. The stock has declined -11.1% during the last week and has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
IDXX is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
IDEXX Laboratories has a current Value Trend Rating of D (Negative). This rating combines highly consistent signals from two proprietary PTR measures of a stock’s attractiveness. IDEXX Laboratories has a slightly negative Appreciation Score of 33 and a slightly negative Power Rating of 31, resulting in the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment